Cancer‐Specific Therapy by Artificial Modulation of Intracellular Calcium Concentration. Issue 18 (31st July 2019)

• Record Type: Journal Article
• Authors: Wang, Cheng; Yu, Fangying; Liu, Xuerong; Chen, Shaoqing; Wu, Rui; Zhao, Rui; Hu, Fuqiang; Yuan, Hong
• Is Part Of: Advanced healthcare materials. Volume 8:Issue 18(2019)
• Page Start: n/a
• Page End: n/a
• Publication Date: 2019-07-31
• Subjects: amorphous calcium carbonate -- apoptosis -- calcium overload -- curcumin -- mitochondria; Biomedical materials -- Periodicals; 610.28
• DOI: 10.1002/adhm.201900501
• Languages: English
• ISSNs: 2192-2640

Abstract

Abstract: Calcium (Ca 2+ ) hemeostasis is crucial for the normal function of cellular biochemistry. The abnormal frequency of Ca 2+ signaling in cancer cells makes them more vulnerable to Ca 2+ modulation than normal cells. Here in this study, a novel cancer‐specific therapy by artificially triggering Ca 2+ overload in cancer cells is proposed. The feasibility of this therapy is illustrated by successful coupling of selective extrusion (Ca 2+ ) inhibition effect of Curcumin (Cur) and the effective Ca 2+ generating capability of amorphous calcium carbonate (ACC) into a facilely prepared water responsive phospholipid (PL)–ACC hybrid platform (PL/ACC–Cur). The obtained results demonstrate that PL/ACC–Cur can specifically boost the intracellular Ca 2+ concentration to cause Ca 2+ overload and to trigger mitochondria‐related apoptosis in MCF‐7 cells while sparing normal hepatocyte (L02), which might be a promising approach for effective cancer therapy. Abstract : A novel cancer‐specific therapy by artificially triggering Ca 2+ overload in cancer cells is proposed. The feasibility is illustrated by coupling the extrusion (Ca 2+ ) inhibition of Curcumin (Cur) and effective Ca 2+ generating of amorphous calcium carbonate (ACC) into a phospholipid (PL)‐ACC hybrid platform (PL/ACC‐Cur). PL/ACC‐Cur can selectively induce Ca 2+ overload and trigger mitochondria‐related apoptosis in MCF‐7 cells.